CAS 56592-32-6

Efrotomicina

Descrição:

Efrotomicina, com o número CAS 56592-32-6, é um antibiótico pertencente à classe dos macrolídeos. É utilizado principalmente por suas propriedades antibacterianas, particularmente contra bactérias Gram-positivas. A substância exibe um mecanismo de ação que envolve a inibição da síntese de proteínas bacterianas, ligando-se à subunidade ribossomal 50S, impedindo assim o crescimento e a reprodução das bactérias. Efrotomicina é caracterizado por seu espectro de atividade relativamente amplo, tornando-o eficaz no tratamento de várias infecções. É tipicamente administrado por injeção e é conhecido por suas propriedades farmacocinéticas, que incluem boa penetração nos tecidos e uma meia-vida moderada. O composto também está sujeito a processos metabólicos no fígado, e sua excreção ocorre principalmente através da bile. Assim como muitos antibióticos, o potencial para desenvolvimento de resistência é uma preocupação, exigindo uso cuidadoso em ambientes clínicos. No geral, Efrotomicina representa uma opção valiosa no arsenal de agentes antimicrobianos, particularmente no tratamento de infecções bacterianas específicas.

Fórmula: C₅₉H₈₈N₂O₂₀

InChI: InChI=1S/C59H88N2O20/c1-15-17-19-27-39-58(8,9)53(80-56-45(67)50(74-13)49(35(7)76-56)79-57-51(75-14)44(66)48(73-12)34(6)77-57)52(68)59(71,81-39)36(16-2)54(69)60-29-23-22-25-32(4)46(72-11)33(5)47-43(65)42(64)38(78-47)26-21-18-20-24-31(3)41(63)40-37(62)28-30-61(10)55(40)70/h15,17-28,30,33-36,38-39,42-53,56-57,62,64-68,71H,16,29H2,1-14H3,(H,60,69)/b17-15-,20-18+,23-22+,26-21+,27-19+,31-24+,32-25+/t33-,34+,35-,36-,38-,39+,42+,43+,44-,45-,46-,47+,48+,49-,50+,51-,52-,53+,56+,57+,59-/m1/s1

Chave InChI: InChIKey=ASOJLQIBBYOFDE-SBHXXGSWSA-N

SMILES: [C@H](C(NC/C=C/C=C(/[C@H]([C@@H](C)[C@@]1(O[C@H](/C=C/C=C/C=C(/C(=O)C=2C(=O)N(C)C=CC2O)\C)[C@H](O)[C@@H]1O)[H])OC)\C)=O)(CC)[C@]3(O)[C@H](O)[C@H](O[C@H]4[C@H](O)[C@H](OC)[C@H](O[C@H]5[C@H](OC)[C@H](O)[C@@H](OC)[C@H](C)O5)[C@@H](C)O4)C(C)(C)[C@H](/C=C/C=C\C)O3

Sinónimos:

• (alphaS,2R,3R,4R,6S)-4-((6-Deoxy-4-O-(6-deoxy-2,4-di-O-methyl-alpha-L-mannopyranosyl)-3-O-methyl-beta-D-allopyranosyl)oxy)-N-((2E,4E,6S,7R)-7-((2S,3S,4R,5R)-5-((1E,3E,5E)-6-(1,2-dihydro-4-hydroxy-1-methyl-2-oxonicotinoyl)-1,3,5-heptatrienyl)tetrahydro-3,4-dihydroxy-2-furyl)-6-methoxy-5-methyl-2,4-octadienyl)-alpha-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-((1E,3Z)-1,3-pentadienyl)-2H-pyran-2-acetamide
• (αS,2R,3R,4R,6S)-4-[[6-Deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-<span class="text-smallcaps">L</smallcap>-mannopyranosyl)-3-O-methyl-β-<smallcap>D</span>-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrien-1-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadien-1-yl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-(1E,3Z)-1,3-pentadien-1-yl-2H-pyran-2-acetamide
• 2H-Pyran-2-acetamide, 4-[[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-<span class="text-smallcaps">L</smallcap>-mannopyranosyl)-3-O-methyl-β-<smallcap>D</span>-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrien-1-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadien-1-yl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-(1E,3Z)-1,3-pentadien-1-yl-, (αS,2R,3R,4R,6S)-
• 2H-Pyran-2-acetamide, 4-[[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-<span class="text-smallcaps">L</smallcap>-mannopyranosyl)-3-O-methyl-β-<smallcap>D</span>-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrienyl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadienyl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-[(1E,3Z)-1,3-pentadienyl]-, (αS,2R,3R,4R,6S)-
• Antibiotic FR 02A
• Brn 5230192
• Efrotomicina
• Efrotomicina [Spanish]
• Efrotomycin A₁
• Efrotomycin [USAN:INN:BAN]
• Efrotomycine
• Efrotomycine [French]
• Fr 02A
• Mk-621
• Mocimycin, 31-O-(6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-alpha-L-mannopyranosyl)-3-O-methyl-beta-D-allopyranosyl)-1-methyl-
• Mocimycin, 31-O-[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-<span class="text-smallcaps">L</smallcap>-mannopyranosyl)-3-O-methyl-β-<smallcap>D</span>-allopyranosyl]-1-methyl-
• Producil
• Unii-5Bpj82Q45X
• (αS,2R,3R,4R,6S)-4-[[6-Deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-L-mannopyranosyl)-3-O-methyl-β-D-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrien-1-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadien-1-yl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-(1E,3Z)-1,3-pentadien-1-yl-2H-pyran-2-acetamide
• 2H-Pyran-2-acetamide, 4-[[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-L-mannopyranosyl)-3-O-methyl-β-D-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrienyl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadienyl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-[(1E,3Z)-1,3-pentadienyl]-, (αS,2R,3R,4R,6S)-
• 2H-Pyran-2-acetamide, 4-[[6-deoxy-4-O-(6-deoxy-2,4-di-O-methyl-α-L-mannopyranosyl)-3-O-methyl-β-D-allopyranosyl]oxy]-N-[(2E,4E,6S,7R)-7-[(2S,3S,4R,5R)-5-[(1E,3E,5E)-7-(1,2-dihydro-4-hydroxy-1-methyl-2-oxo-3-pyridinyl)-6-methyl-7-oxo-1,3,5-heptatrien-1-yl]tetrahydro-3,4-dihydroxy-2-furanyl]-6-methoxy-5-methyl-2,4-octadien-1-yl]-α-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-(1E,3Z)-1,3-pentadien-1-yl-, (αS,2R,3R,4R,6S)-

Efrotomycin

CAS: 56592-32-6

Efrotomycin: an oral antibiotic from Streptomyces Lactamdurans; minimal effect on Salmonella in pigs.

Fórmula: C₅₉H₈₈N₂O₂₀

Cor e Forma: Solid

Peso molecular: 1145.33

Ref: TM-T73910